The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Zanubrutinib plus venetoclax for patients with CLL
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, shares his insights into the use of selective next-generation Bruton’s tyrosine kinase (BTK) inhibitors, by presenting some early results from arm D of the SEQUOIA (BGB-3111-304; NCT03336333) trial. Dr Hillmen discusses the findings from this trial, including the high tolerability and good levels of minimal residual disease (MRD) eradication observed when using zanubrutinib in combination with venetoclax for del(17p) patients with chronic lymphocytic leukemia (CLL). This interview was filmed at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
